Regulatory Blog

The integrity, reliability, and robustness of clinical trial data are fundamental to regulatory decision-making, particularly for marketing authorisation applications (MAAs). With the increasing reliance on computerised systems such as electronic case report forms (eCRFs), electronic patient-reported outcomes (ePROs), safety databases, interactive response technologies (eIRT), and clinical trial management systems (CTMS), the role of validated digital systems has become centr